Cite
HARVARD Citation
Werth, V. et al. (n.d.). FRI0470 A phase 2 study of safety and efficacy of lenabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis. Annals of the rheumatic diseases. pp. 763-764. [Online].